On the one hand, SGLT-2 inhibitors can improve insulin resistance, increase glucose excretion in urine by competitively blocking sodium–glucose co-transporter in the renal proximal convoluted tubules, reduce insulin level, improve insulin resistance and reduce stimulation of fat regeneration [51]. The gene discussed is INS; the disease is Insulin resistance.